Back
Centrus Energy 10K Form
Sell
40
LEU
Centrus Energy
Last Price:
49.16
Seasonality Move:
8.02%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-08 | 10Q | LEU/Centrus Energy Quarterly |
| 2023-08-04 | 10Q | LEU/Centrus Energy Quarterly |
| 2023-05-09 | 10Q | LEU/Centrus Energy Quarterly |
| 2022-11-09 | 10Q | LEU/Centrus Energy Quarterly |
| 2022-08-05 | 10Q | LEU/Centrus Energy Quarterly |
| 2022-05-06 | 10Q | LEU/Centrus Energy Quarterly |
Receive LEU News And Ratings
See the #1 stock for the next 7 days that we like better than LEU
LEU Financial Statistics
Sales & Book Value
| Annual Sales: | $293.8M |
|---|---|
| Cash Flow: | $-24.4M |
| Price / Cash Flow: | 16.7 |
| Annual Sales: | $-1.55 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | 3.14000 |
|---|---|
| Net Income (TTM): | $49.4M |
| Gross Margin: | $117.9M |
| Return on Equity: | 0% |
| Return on Assets: | 7.22% |
Centrus Energy Earnings Forecast
Key Centrus Energy Financial Ratios
- The Gross Profit Margin over the past 25 years for LEU is 40.13%.
- The Selling, General & Administrative Expenses for LEU have been equal to 11.54% of Gross Profit Margin.
- The Research & Development expenses have been 13.52% of Revenue.
- The Interest Expense is 0.96% of Operating Income.
- The Net Earning history of LEU is 17.77% of Total Revenues.
- Per Share Earnings over the last 25 years have been positive in 13 years.
Centrus Energy Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NYAM |
|---|---|
| Industry: | Uranium |
| Sector: | Energy |
| Current Symbol: | LEU |
| CUSIP: | 15643U |
| Website: | centrusenergy.com |
Debt
| Debt-to-Equity Ratio: | -7.1 |
|---|---|
| Current Ratio: | 1.58 |
| Quick Ratio: | 0.57 |
Price-to-Earnings
| Trailing P/E Ratio: | 14.52 |
|---|---|
| Forward P/E Ratio: | 19.14 |
LEU Technical Analysis vs Fundamental Analysis
Sell
40
Centrus Energy (LEU)
is a Sell
Is Centrus Energy a Buy or a Sell?
-
Centrus Energy stock is rated a Sell
The current Centrus Energy [LEU] share price is $49.09. The Score for LEU is 40, which is 20% below its historic median score of 50, and infers higher risk than normal.